US 12122998
Materials and methods for treatment of usher syndrome type 2A and/or non-syndromic autosomal recessive retinitis pigmentosa (ARRP)
granted A61KA61K35/12A61K38/00
Quick answer
US patent 12122998 (Materials and methods for treatment of usher syndrome type 2A and/or non-syndromic autosomal recessive retinitis pigmentosa (ARRP)) held by CRISPR THERAPEUTICS AG expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- CRISPR THERAPEUTICS AG
- Grant date
- Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 22
- CPC classes
- A61K, A61K35/12, A61K38/00, A61K48/0066, A61P